论文部分内容阅读
目的研制一种适于皮下植入的缓释剂型，用于脱敏治疗。方法把３Ｈ标记的尘螨变应原（３Ｈ－ＤＦＡ）固定于壳聚糖中，制成ＤＦＡＣ植入片，埋植家兔皮下，用液闪计数仪测定其缓释作用。结果ＤＦＡＣ不崩解，１８０ｄ降解率为（８．１０±２．３１）％，具有较稳定的缓释作用。结论ＤＦＡＣ可用作长效缓释植入剂并有良好前景。
Objective To develop a sustained release dosage form suitable for subcutaneous implantation for desensitization treatment. Methods The 3H labeled Dust mite allergen (3H-DFA) was immobilized on chitosan to make DFAC implants, and the implants were subcutaneously implanted in rabbits. The sustained-release effect was determined by liquid scintillation counter. Results DFAC did not disintegrate, and the degradation rate was (8.10 ± 2.31)% after 180d, which showed a more stable sustained release effect. Conclusion DFAC can be used as long-acting sustained-release implants and has good prospects.